Most studies identified that high expression of CD163 was closely associated with poor prognosis in multiple cancers,[41,42] but Pelekanou et al[43] demonstrated that high levels of CD163 may be related to favorable prognosis in breast cancer. This evidence concerns the gene CD163 and breast carcinoma.